| Essential Hypertension
Azor vs Edarbi
Side-by-side clinical, coverage, and cost comparison for essential hypertension.Deep comparison between: Azor vs Edarbi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEdarbi has a higher rate of injection site reactions vs Azor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Edarbi but not Azor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Azor
Edarbi
At A Glance
Oral
Once daily
CCB / ARB combination
Oral
Once daily
Angiotensin II receptor blocker
Indications
- Essential Hypertension
- Essential Hypertension
Dosing
Essential Hypertension Starting dose 5/20 mg once daily; may be increased after 1-2 weeks to a maximum of 10/40 mg once daily as needed to control blood pressure.
Essential Hypertension 80 mg orally once daily; consider a starting dose of 40 mg for patients treated with high doses of diuretics. May be administered with or without food and with other antihypertensive agents.
Contraindications
- Co-administration of aliskiren in patients with diabetes
- Coadministration of aliskiren-containing products in patients with diabetes
Adverse Reactions
Most common (>=3%) Edema
Postmarketing (amlodipine) Gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder
Postmarketing (olmesartan medoxomil) Asthenia, angioedema, anaphylactic reactions, peripheral edema, vomiting, diarrhea, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, alopecia, pruritus, urticaria
Most common diarrhea, nausea, asthenia, fatigue, muscle spasm, dizziness, dizziness postural, cough
Postmarketing rash, pruritus, angioedema
Pharmacology
Azor combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium ion influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance, with olmesartan medoxomil, an angiotensin II receptor blocker that selectively blocks AT1 receptors in vascular smooth muscle to oppose the vasoconstrictor effects of angiotensin II.
Azilsartan is an angiotensin II receptor blocker (ARB) that selectively blocks binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, inhibiting vasoconstriction and aldosterone secretion; azilsartan medoxomil is a prodrug rapidly converted to azilsartan by esterases during gastrointestinal absorption.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Azor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Edarbi
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (7/12) · Qty limit (11/12)
UnitedHealthcare
Azor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Edarbi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Azor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (1/3)
Edarbi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Azor.
No savings programs available for Edarbi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.